News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAlliance Pharma Announces the Execution of its Licensing Agreement With Vestiq Pharmaceuticals for Oravig® in the U.S.


9/24/2012 10:10:10 AM

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO) (Paris:BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig® in the United States (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis in adults.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES